Drug Interactions between Carbocaine 2% with Neo-Cobefrin and trifluoperazine
This report displays the potential drug interactions for the following 2 drugs:
- Carbocaine 2% with Neo-Cobefrin (levonordefrin/mepivacaine)
- trifluoperazine
Interactions between your drugs
trifluoperazine levonordefrin
Applies to: trifluoperazine and Carbocaine 2% with Neo-Cobefrin (levonordefrin / mepivacaine)
GENERALLY AVOID: Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors. Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect. Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.
MANAGEMENT: Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents. Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.
References
- Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC "Chlorpromazine: a study of its action on the circulation in man." Lancet 2 (1954): 614-7
- Ginsburg J, Duff RS "Effect of chlorpromazine on adrenaline vasoconstriction in man." Br J Pharmacol 11 (1956): 180-5
- "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham PROD (2002):
- "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories PROD (2001):
- "Product Information. Navane (thiothixene)." Roerig Division PROD (2001):
- Lear E, Chiron AE, Pallin IM "A clinical study of mechanisms of action of chlorpromazine." JAMA 163 (1957): 30-6
- Gonzalez ER "Catecholamine selection for vasopressor-dependent patients." Clin Pharm 7 (1988): 493, 496
- "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals PROD (2001):
- Goulet JP, Perusse R, Turcotte JY "Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions." Oral Surg Oral Med Oral Pathol 74 (1992): 692-7
- "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company PROD (2001):
- "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals PROD (2001):
- "Product Information. Moban (molindone)." Gate Pharmaceuticals PROD (2001):
- "Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc PROD (2001):
- "Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Loxitane C (loxapine)." Apothecon Inc (2022):
- Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S "Chronic chlorpromazine administration: some pharmacological and psychological effects in man." Clin Pharmacol Ther 6 (1965): 575-86
- "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb (2002):
- "Product Information. Invega (paliperidone)." Janssen Pharmaceuticals (2007):
Drug and food interactions
trifluoperazine food
Applies to: trifluoperazine
GENERALLY AVOID: Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment. Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines. The two drugs probably act on different sites in the brain, although the exact mechanism of the interaction is not known.
MANAGEMENT: Patients should be advised to avoid alcohol during phenothiazine therapy.
References
- Lutz EG "Neuroleptic-induced akathisia and dystonia triggered by alcohol." JAMA 236 (1976): 2422-3
- Freed E "Alcohol-triggered-neuroleptic-induced tremor, rigidity and dystonia." Med J Aust 2 (1981): 44-5
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.